Harvard Bioscience ( (HBIO) ) has released its Q2 earnings. Here is a breakdown of the information Harvard Bioscience presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Harvard Bioscience, Inc. is a prominent developer and manufacturer in the life sciences sector, providing essential technologies for research, drug discovery, and preclinical testing, with a global presence across the United States, Europe, and China.
In its latest earnings report for the second quarter of 2025, Harvard Bioscience announced revenues of $20.5 million, a slight decrease from the previous year, alongside a gross margin of 56.4%. The company also highlighted a positive cash flow from operations, signaling strong financial discipline and operational improvements.
Key financial metrics from the report include a net loss of $2.3 million, an improvement from the $2.9 million loss in the same quarter last year, and an adjusted EBITDA of $1.5 million, up from $1.3 million. The company also secured a new credit amendment, extending its refinance deadline to December 5, 2025, which reflects its strategic focus on restructuring its balance sheet.
Looking ahead, Harvard Bioscience anticipates third-quarter revenues between $19 million and $21 million, with gross margins expected to remain in the 56% to 58% range. The company is optimistic about its growth prospects, driven by its commitment to enhancing core business operations and financial restructuring.
Overall, Harvard Bioscience is poised for future growth, with management focusing on revenue expansion and margin improvements as they navigate the evolving market landscape.